Vera Therapeutics develops drug candidates for serious immune system diseases, led by atacicept for IgA nephropathy, a kidney disease. It last closed at $25.45 on Nov 20, down 4.86% on the day. The next earnings report for VERA is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, VERA reported EPS of -$1.30 on revenue of $10.3M. Over its last 8 reports the stock moved an average of 3.4% the session after earnings. Over the last 12 months VERA insiders bought $250K of stock on the open market and sold $8.6M, according to SEC Form 4 filings.
AI Auto Pilots
Is VERA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VERA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on VERAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
VERA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 14% below its 20 day and 19% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $25.08, and the nearest resistance the Pivot at $25.92.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.5%/day
Key levels
$56.0552 week high+120.2%
$35.71200 day average+40.3%
$32.73100 day average+28.6%
$31.84Swing high (Oct 22)+25.1%
$30.2550 day average+18.9%
$29.1420 day average+14.5%
$26.68Pivot R1+4.8%
$25.92Pivot+1.8%
$25.45Last close
$25.0852 week low−1.5%
$24.69Pivot S1−3.0%
Indicators
RSI (14)
35.94
Weak, oversold below 30
Neutral
MACD
-1.13
Below its signal line
Bearish
Stochastic
10.0
Near the bottom of its range
Oversold
ADX (14)
16.7
No clear trend
Williams %R
-94.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-134.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.6%
Change over 10 sessions
Bearish
ATR (14)
$1.65
Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 16.6%/day
Key levels
$56.0552 week high+120.2%
$35.71200 day average+40.3%
$32.73100 day average+28.6%
$31.84Swing high (Oct 22)+25.1%
$30.2550 day average+18.9%
$29.1420 day average+14.5%
$26.68Pivot R1+4.8%
$25.92Pivot+1.8%
$25.45Last close
$25.0852 week low−1.5%
$24.69Pivot S1−3.0%
Indicators
RSI (14)
34.90
Weak, oversold below 30
Neutral
MACD
-2.47
Below its signal line
Bearish
Stochastic
16.9
Near the bottom of its range
Oversold
ADX (14)
14.6
No clear trend
Williams %R
-96.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-141.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.4%
Change over 10 sessions
Bearish
ATR (14)
$4.21
Typical daily range, 16.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how VERA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow VERA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for VERAHow many large options trades hit VERA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in VERA in the last 90 days.
From SEC Form 4 filings by VERA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERA is in one of them and how their past VERA trades turned out.
Vera Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for serious immune system diseases, with a focus on kidney conditions. Its lead candidate, atacicept, is being studied for IgA nephropathy, a kidney disease, and other autoimmune kidney disorders, and is designed to be given at home by autoinjector. The company also holds rights to MAU868, which is being studied for BK viremia in kidney transplant patients, and to VT109, a preclinical candidate. Its target customers are patients with these conditions and the doctors who treat them.